Page 7 - Axsm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Axsm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Axsm Today - Breaking & Trending Today

Axsome Therapeutics, Inc. (NASDAQ:AXSM) to Post Q3 2023 Earnings of ($1.31) Per Share, Zacks Research Forecasts

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) – Equities research analysts at Zacks Research lowered their Q3 2023 earnings per share estimates for Axsome Therapeutics in a research note issued to investors on Monday, August 21st. Zacks Research analyst K. Shah now anticipates that the company will earn ($1.31) per share for the quarter, down […] ....

United States , Piper Sandler , Axsome Therapeutics Inc , Zacks Research , China Universal Asset Management Co , Victory Capital Management Inc , Ameritas Investment Partners Inc , Morgan Stanley , Tower Research Capital , Axsome Therapeutics Company Profile , Capital Management , Axsome Therapeutics , Free Report , Axsome Therapeutic , Therapeutics Stock Down , Universal Asset Management , Investment Partners , Research Capital , Victory Capital Management , Get Free Report , Axsome Therapeutics Daily , Nasdaq Axsm , Earnings Estimates ,

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $100.00

Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its target price lifted by Mizuho from $95.00 to $100.00 in a research report released on Friday morning, MarketBeat Ratings reports. They currently have a buy rating on the stock. Several other research analysts also recently weighed in on AXSM. HC Wainwright dropped their target price on shares […] ....

United States , Piper Sandler , Axsome Therapeutics Inc , Boxer Capital , Vr Adviser , Axsome Therapeutics , Free Report , Marketbeat Ratings , Moderate Buy , Deep Track Capital , Get Free Report , Axsome Therapeutics Daily , Nasdaq Axsm , Boost Price Target ,

Axsome Therapeutics (NASDAQ:AXSM) Given New $180.00 Price Target at HC Wainwright

Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its price target lowered by HC Wainwright from $190.00 to $180.00 in a research report released on Tuesday, Marketbeat reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Axsome Therapeutics’ Q3 2023 earnings at ($1.12) EPS, Q4 2023 earnings at […] ....

United States , Piper Sandler , William Blair , China Universal Asset Management Co , Axsome Therapeutics Company Profile , Pricet Rowe Associates Inc , Victory Capital Management Inc , Morgan Stanley , Axsome Therapeutics Inc , Capital Management , Ameritas Investment Partners Inc , Axsome Therapeutics , Free Report , Moderate Buy , Therapeutics Stock Down , Universal Asset Management , Investment Partners , Pricet Rowe Associates , Get Free Report , Axsome Therapeutics Daily , Nasdaq Axsm , Lower Price Target , Hc Wainwright ,

Axsome Therapeutics' (AXSM) Outperform Rating Reaffirmed at William Blair

William Blair reiterated their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research note issued to investors on Monday morning, RTT News reports. A number of other analysts have also issued reports on the company. Mizuho boosted their price target on Axsome Therapeutics from $84.00 to $95.00 in a report […] ....

United States , William Blair , Axsome Therapeutics Inc , International Biotechnology Trust , Oak Ridge Investments , Morgan Stanley , Principal Financial Group Inc , Axsome Therapeutics , Free Report , Moderate Buy , Get Free Report , Biotechnology Trust , Financial Strategies , Financial Group , Axsome Therapeutics Daily , Nasdaq Axsm , Reiterated Rating ,

Envestnet Asset Management Inc. Sells 1,548 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Envestnet Asset Management Inc. reduced its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 12.9% in the 1st quarter, HoldingsChannel.com reports. The fund owned 10,473 shares of the company’s stock after selling 1,548 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Axsome Therapeutics were worth $646,000 at the end […] ....

United States , Axsome Therapeutics Company Profile , Envestnet Asset Management Inc , Morgan Stanley , Jpmorgan Chase Co , Axsome Therapeutics Inc , Raymond James Financial Services Advisors Inc , Panagora Asset Management Inc , Sei Investments Co , Metlife Investment Management , Envestnet Asset Management , Axsome Therapeutics , Free Report , Asset Management , James Financial Services Advisors , Life Investment Management , Sei Investments , Get Free Report , Visit Holdingschannel , Axsome Therapeutics Daily , Nasdaq Axsm , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,